- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001255
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study
Treatment of Severe Combined Immunodeficiency Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency With Autologous Lymphocytes of CD34+ Cells Transduced With a Human ADA Gene: A Natural History Study
This study will monitor the long-term effects of gene therapy in patients with severe combined immunodeficiency disease (SCID) due to a deficiency in an enzyme called adenosine deaminase (ADA). It will also follow the course of disease in children who are not receiving gene therapy, but may have received enzyme replacement therapy with the drug PEG-ADA.
ADA is essential for the growth and proper functioning of infection-fighting white blood cells called T and B lymphocytes. Patients who lack this enzyme are, therefore, immune deficient and vulnerable to frequent infections. Injections of PEG-ADA may increase the number of immune cells and reduce infections, but this enzyme replacement therapy is not a definitive cure. In addition, patients may become resistant or allergic to the drug. Gene therapy, in which a normal ADA gene is inserted into the patient's cells, attempts to correcting the underlying cause of disease.
Patients with SCID due to ADA deficiency may be eligible for this study. Patients may or may not have received enzyme replacement therapy or gene transfer therapy, or both. Participants will have follow-up visits at the National Institutes of Health in Bethesda, Maryland, at least once a year for a physical examination, blood tests, and possibly the following additional procedures to evaluate immune function:
- Bone marrow sampling - A small amount of marrow from the hip bone is drawn (aspirated) through a needle. The procedure can be done under local anesthesia or light sedation.
- Injection of small amounts of fluids into the arm to study if the patient's lymphocytes respond normally.
- Administration of vaccination shots.
- Collection of white blood cells through apheresis - Whole blood is collected through a needle placed in an arm vein. The blood circulates through a machine that separates it into its components. The white cells are then removed, and the red cells, platelets and plasma are returned to the body, either through the same needle used to draw the blood or through a second needle placed in the other arm.
- Blood drawings to obtain and study the patient's lymphocytes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary purpose of this study is to continue to provide clinical follow-up for ADA-deficient patients treated with gene therapy under the original protocol 90-HG-0195 (IND 3624) and its amendments (IND 4647 and IND 5056). The objectives are the long-term monitoring of the beneficial effects of gene therapy and continued surveillance of potential adverse effects associated with the gene transfer procedures.
No new subjects will be enrolled in this protocol.
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Human Genome Research Institute (NHGRI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
New patients will not be treated under protocol 90-HG-0195 as new and improved vectors and technologies have become available in the recent years.
New patients with ADA deficiency, however, may be enrolled in protocol 90-HG-0195 for clinical evaluation of their immune system and pre-treatment testing of transduction procedures.
Study Plan
How is the study designed?
Collaborators and Investigators
Publications and helpful links
General Publications
- Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972 Nov 18;2(7786):1067-9. doi: 10.1016/s0140-6736(72)92345-8. No abstract available.
- Donofrio J, Coleman MS, Hutton JJ, Daoud A, Lampkin B, Dyminski J. Overproduction of adenine deoxynucleosides and deoxynucletides in adenosine deaminase deficiency with severe combined immunodeficiency disease. J Clin Invest. 1978 Oct;62(4):884-7. doi: 10.1172/JCI109201.
- Cohen A, Hirschhorn R, Horowitz SD, Rubinstein A, Polmar SH, Hong R, Martin DW Jr. Deoxyadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc Natl Acad Sci U S A. 1978 Jan;75(1):472-6. doi: 10.1073/pnas.75.1.472.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 900195
- 90-HG-0195
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Combined Immunodeficiency
-
Great Ormond Street Hospital for Children NHS Foundation...UnknownX-linked Severe Combined ImmunodeficiencyUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...RecruitingX-linked Severe Combined Immunodeficiency (XSCID)United States
-
St. Jude Children's Research HospitalNational Heart, Lung, and Blood Institute (NHLBI); Assisi Foundation; California...SuspendedSevere Combined Immunodeficiency Disease, X-linkedUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedX-linked Severe Combined ImmunodeficiencyFrance
-
Shenzhen Geno-Immune Medical InstituteUnknownAdenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)China
-
David WilliamsActive, not recruitingGene Therapy | Severe Combined Immunodeficiency, X LinkedUnited States, United Kingdom
-
National Institute of Allergy and Infectious Diseases...TerminatedGrowth Failure | X-linked Severe Combined Immunodeficiency (XSCID) | Growth Hormone ResistenceUnited States
-
Great Ormond Street Hospital for Children NHS Foundation...RecruitingSevere Combined Immunodeficiency, X-LinkedUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...UnknownX-Linked Combined Immunodeficiency DiseasesUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedSevere Combined ImmunodeficiencyUnited States
Clinical Trials on ADA PBSC
-
Ada Health GmbHBabes-Bolyai University; Botnar FoundationCompletedMental Health Issues | Gastrointestinal Issues | Respiratory Issues | Cardiovascular Issues | Genitourinary Issues | Musculoskeletal Issues | ENT Issues | Eye Issues | Neurologic IssuesRomania
-
Ada Health GmbHMuhimbili University of Health and Allied SciencesActive, not recruitingNeurological Conditions | Mental Health Conditions | Abdominal Pain/Gastrointestinal Issues | Lower Respiratory System Conditions | Upper Respiratory System Conditions | Ophthalmology Conditions | Orthopedic Conditions | Cardiovascular System Conditions | Genitourinary System Conditions | ENT Conditions | Dermatology Conditions and other conditionsTanzania
-
Hospital de Clinicas de Porto AlegreTerminated
-
Siel BleuInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingQuality of Life | Breast CancerFrance
-
University of Massachusetts, WorcesterCompletedLow-GI Dietary Education | ADA Dietary EducationUnited States
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaboratorsUnknownHematological Diseases | Stem Cell Transplantation, Hematopoietic | Delayed Platelet Engraftment | Poor Graft FunctionChina
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Sun Yat-sen University; Shanghai Zhongshan... and other collaboratorsUnknownPeripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft FunctionHematological Diseases | Stem Cell Transplantation, Hematopoietic | Poor Graft FunctionChina
-
Adapt Produtos Oftalmológicos Ltda.Unknown
-
Hadassah Medical OrganizationCompletedObese Type 2 Diabetic Patients
-
Morehouse School of MedicineEmory UniversityRecruiting